Evidence map›Paper›PMID 25565572›Full record

ReviewCurrent opinion in pediatrics2015

Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders.

Shalini Shenoy, Jaap J Boelens

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in pediatrics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. In vivo engineering of bone tissues with hematopoietic functions and mixed chimerism.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Shalini ShenoyaDepartment of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA bUniversity Medical Center Utrecht, Pediatric Blood and Marrow Transplantation Program cLaboratory Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
Jaap J Boelens
St. Louis Children's Hospital · USUniversity Medical Center Utrecht · NL

Funding

Pediatric Blood and Marrow Transplant ConsortiumU01HL069254 · NHLBI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI PULSIPHER, MICHAEL A · 2001 to 2010
$2.0M
NHLBI NIH HHS U01HL065268NHLBI NIH HHS U01 HL069254NHLBI NIH HHS U01HL069254
6 · The paper itself

Abstract

purpose of reviewThe role of hematopoietic cell transplantation in non-malignant disorders has increased exponentially with the recognition that multiple diseases can be controlled or cured if engrafted with donor-derived cells. This review provides an overview of advances made in alternative donor transplants for nonmalignant disorders. RECENT

findingsStem cell sources, novel transplant methods, and sophisticated supportive care have simultaneously made giant strides toward improving the safety and efficacy of hematopoietic cell transplantation. This has led to the utilization of marrow, cord, peripheral blood stem cell and haploidentical stem cell sources, and novel reduced toxicity or reduced intensity conditioning regimens to transplant non-malignant disorders such as immune dysfunctions, marrow failure syndromes, metabolic disorders and hemoglobinopathies. Transplant complications such as graft rejection, infections, and graft versus host disease are better combated in this modern era of medicine, achieving better survival with decreased late effects. These aspects of transplant for non-malignant disorders are discussed. SUMMARY: This review presents the progress made in the realm of hematopoietic cell transplantation for non-malignant disorders. It advocates the consideration of alternative donor transplants in the absence of human leukocyte antigen matched siblings when indicated by disease severity. The ultimate goal is to provide curative transplant options for more patients that can benefit from this intervention, prior to detrimental outcomes.

Indexed as

Cord Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationChildChild, PreschoolGraft RejectionHumansImmune System DiseasesTissue and Organ HarvestingTissue DonorsTransplantation Conditioning

Identifiers

PMID25565572
PMCPMC4403859
OpenAlexW1967796009

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.